Powering Precise Protein Assays
Standardized Prospective Biospecimen Collection Strengthens Biomarker Studies
The future of clinical research depends heavily on prospective biospecimen collection. This means collecting fresh, purpose-built samples under a defined protocol, rather than pulling from older banked material.
Done well, prospective biospecimen collection strengthens the rigor and reliability of research findings. It helps researchers draw meaningful insights from clinical data and supports high-quality, reproducible results in translational studies. Careful planning and consistent execution are key: a systematic approach reduces variability, improves outcomes in biomarker research, and streamlines the path from sample to therapy.
“Slow is smooth, smooth is fast.” This Navy SEAL slogan captures something true about high-content analysis experiments. Taking time to get study design, sample procurement, and data collection right — especially through prospective biospecimen collection — leads to more informative results and better overall efficiency.
This matters a lot for protein assays, which are essential tools for measuring how the immune system responds to therapies. Protein-based immunogenicity assays can assess a patient’s immune response to a vaccine, or help identify anti-drug antibodies (ADAs) during drug and gene therapy development. Protein assays are also central to biomarker validation, a cornerstone of evaluating safety and efficacy in therapeutic development. This data is important for closing the gap between lab research and patient care. That means it needs to come from samples collected consistently — through prospective biospecimen collection.
Poor, unreliable protein data wastes time and resources. Non-standardized protocols for obtaining biospecimens — especially in prospective biospecimen collection — can hurt sample quality and introduce variability. This happens when the timing and method of collection, processing, and storage aren’t controlled. Regulatory agencies have taken notice. The National Institute of Standards and Technology and the Food and Drug Administration have launched initiatives to promote standardized practices for developing advanced therapeutics such as cell and gene therapies.
Researchers also often face limited access to patient information and to sufficient sample quantities. This further reduces the value they can extract from these precious resources. Turning to more robust, reliable, and consistent methods of sample procurement — including prospective biospecimen collection — helps avoid these pitfalls. It supports the most accurate results possible.
Standardized Procurement and Processing Methods for More Reliable Data
Past studies show that inconsistent handling of “starting materials” can skew immunogenicity assay results. For example, differences in storage buffer and temperature can significantly change the stability of human monoclonal antibodies [Zhang 2006]. Antibody stability can influence protein assay results. That’s a strong argument for optimized, consistent procurement and storage protocols, particularly in prospective biospecimen collection [Ma 2020].
Choosing the right protein source matters just as much. Peripheral blood mononuclear cells (PBMC) — the circulating immune cells in blood — are a common source material for measuring the immunogenicity of therapeutic proteins and treatments. More recently, researchers have turned to leukapheresis to collect leukopaks as source material for isolating immune cells such as lymphocytes and PBMC. Leukopaks offer real advantages over isolating PBMC directly from whole blood:
- Higher concentrations of immune cells
- Less contamination from plasma and other cell types
- Reduced sample variability and cleaner data [Garcia 2014, Akadeum 2023]
Choosing the right starting material for immune cell isolation helps ensure valid, successful protein assays in translational research. This matters particularly when samples are derived through prospective biospecimen collection.
Access to Large and Diverse Patient Populations
Protein assays used for biomarker identification and drug pharmacology let translational researchers predict how later clinical trials are likely to go. There’s also a growing push to make translational research more equitable and inclusive by studying diverse patient populations. This promotes greater health equity [Boulware 2022, Dolgin 2023]. Access to large, diverse cohorts of healthy and disease-state donors that closely resemble clinical trial populations reduces risk and leads to more robust predictions. This is especially important for samples from patients with confirmed disease, which are often hard to obtain due to limited availability.
Sample procurement has traditionally relied on retrospective biobanks. This approach limits access to specific patient populations and control over how samples are collected, stored, and processed. Prospective methods of sample procurement look more like how clinical trials are actually run. They can provide adequate sample quantities in a standardized, streamlined way. They also give researchers the tools to obtain enough rare disease samples while dictating collection and processing procedures for consistent, reliable results. Examples include mobile phlebotomy in the homes of Sanguine‘s extensive population of diverse healthy and disease-state donors, and onsite collection programs for healthy employees at laboratory or office complexes.
Sanguine also offers healthy and disease-state leukopaks. These can save translational researchers time and effort on protein assays. They provide a greater concentration and selection of immune cell targets from a single donor than traditional PBMC isolation. Researchers can screen initial donor samples for protein assay performance to identify ideal leukapheresis candidates for recall, or access existing inventory. Together, these options give translational researchers the tools to design robust, powerful patient studies and develop therapies more efficiently through prospective biospecimen collection.
Patient Access for More Informative Study Design
Translational researchers need enough access to patient information and follow-up data to draw valid conclusions and get the most out of their results. Comprehensive patient metadata lets researchers stratify participants into subgroups based on specific characteristics. This helps identify biomarkers that predict disease severity or a patient’s response to therapy.
Human leukocyte antigen (HLA) typing is a good example of how powerful this can be for protein assays used in translational research. A study published in Cell looked at whether T-cell epitopes presented by HLAs could serve as an alternative vaccine target to antibodies in COVID-19 vaccine development. The authors used HLA typing to screen convalescent and healthy patients for expression of the HLA-A*02:01 allele. This allele produced the strongest CD8+ response in early in vitro testing. By obtaining peripheral blood and PBMCs from this patient population, researchers characterized the T-cell response to various HLA peptides through tetramer and ELISpot assays. This work identified specific T-cell epitopes that are promising targets for next-generation COVID-19 vaccine development [Weingarten-Gabbay 2021].
Alongside comprehensive donor data, researchers may need extensive, continual access to donors to run longitudinal and prospective studies. These studies get the most value from protein assay data. This is particularly relevant for protein immunogenicity assays, since they let researchers track therapeutic response over time in a way that more closely matches later clinical trials and real-world outcomes.
Longitudinal translational studies have also proven valuable for biomarker discovery. Monitoring clinical biomarkers over longer periods in response to treatment can reveal new biological connections. It can also help distinguish individual differences from average population trends [Westerman 2018, Albert 2012]. Taken together, a longitudinal approach to immunogenicity and biomarker discovery lets translational researchers draw more meaningful, powerful conclusions from their data — especially through prospective biospecimen collection.
The Sanguine Solution
Protein assays are a hallmark of the translational process that turns bench discoveries into bedside treatments. Researchers and patients both benefit when biospecimen procurement follows standardized methods — particularly prospective biospecimen collection — in line with regulatory guidelines. This supports greater sample consistency and better patient access. To meet these needs with a more standardized, streamlined, and effective approach, Sanguine offers unique procurement programs that give translational researchers the tools they need to succeed.
By working with researchers to align sample collection and processing with their clinical study designs, Sanguine’s approach reduces concerns about sample quality and consistency. This improves the results researchers get from their protein assays.
Sanguine also offers access to large, diverse, and recallable patient populations, supporting robust longitudinal study designs for specific patient groups, including rare diseases and autoimmune conditions. With enough patient information and metadata on hand, researchers can make more relevant comparisons and stratify patients by disease severity or treatment response. This enhances biomarker discovery and speeds up validation.
Find out if Sanguine’s approach is right for you by learning more about our services for researchers.
By: William Lawrence, Ph.D.; Geocyte
References
[1] Zhang, JY. (2006) Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. International Journal of Pharmaceutics. Vol 308: 46-51. DOI: https://doi.org/10.1016/j.ijpharm.2005.10.024
[2] Ma, H. (2020) Antibody stability: A key to performance – Analysis, influences and improvement. Biochimie. Vol 177: 213-225. DOI: https://doi.org/10.1016/j.biochi.2020.08.019
[3] Garcia, A. (2014) Leukopak PBMC Sample Processing for Preparing Quality Control Material to Support Proficiency Testing Programs. J Immunol Methods. Vol 409: 99-106. DOI: 10.1016/j.jim.2014.05.019
[4] Akadeum (2023). Leukopak Processing: Pan T Cell Isolation From Leukopaks. Akadeum Life Sciences. https://www.akadeum.com/applications/leukopak-processing/
[5] Boulware, LE. (2022) Combating Structural Inequities — Diversity, Equity, and Inclusion in Clinical and Translational Research. Engl J Med. 386: 201-203. DOI: 10.1056/NEJMp2112233
[6] Dolgin, E. (2023) Scientists Unveil a More Diverse Human Genome. The New York Times. https://www.nytimes.com/2023/05/10/science/pangenome-human-dna-genetics.html
[7] Weingarten-Gabbay, S. (2021) Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. Cell. 184: 3962-3980. DOI: 10.1016/j.cell.2021.05.046
[8] Westerman, K. (2018) Longitudinal analysis of biomarker data from a personalized nutrition platform in healthy subjects. Scientific Reports. 8: 14865. DOI: https://doi.org/10.1038/s41598-018-33008-7
[9] Albert, PS. (2012) Novel statistical methodology for analyzing longitudinal biomarker data. Stat Med. Stat Med. 22: 2457-2460. DOI: 10.1002/sim.5500.
